Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

This randomized, placebo-controlled, cross-over, double-blind study aimed to investigate the effects of high dose, short-term (5 weeks) treatment with liraglutide in obese patients with no overt type 2 diabetes on the levels of circulating metabolites and detailed lipid profile.

Several cardiometabolic markers were affected by varying degree. Treatment of obese patients without overt type 2 diabetes with liraglutide induced changes in lipid and hormonal profiles that are suggestive of lower risk of atherosclerosis and cardiovascular disease.

Stay in the know

Our latest health headlines delivered to your inbox.